SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]
SEC Accession No. 0001214659-21-003892
Filing Date
2021-04-02
Accepted
2021-04-02 16:11:34
Documents
1
Period of Report
2021-03-26

Document Format Files

Seq Description Document Type Size
1 PRIMARY DOCUMENT marketforms-52165.html 4/A  
1 PRIMARY DOCUMENT marketforms-52165.xml 4/A 7284
  Complete submission text file 0001214659-21-003892.txt   8678
Mailing Address C/O ALLOGENE THERAPEUTICS, INC. 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address
Chang David D (Reporting) CIK: 0001611024 (see all company filings)

Type: 4/A | Act: 34 | File No.: 001-38693 | Film No.: 21802079

Mailing Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 457-2700
Allogene Therapeutics, Inc. (Issuer) CIK: 0001737287 (see all company filings)

IRS No.: 823562771 | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)